SGLT2抑制剂与GLP-1受体激动剂对2型糖尿病患者心血管影响的研究  

Influence of SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular system in patients with type 2 diabetes mellitus

作　　者：高舒荃 梁梅花[1] GAO Shu-quan;LIANG Mei-hua(Department of Endocrinology and Metabolic Diseases,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院内分泌与代谢病科,黑龙江哈尔滨150081

出　　处：《心血管康复医学杂志》2023年第2期170-173,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：2型糖尿病(T2DM)患者容易并发微血管和大血管病变,是心血管疾病发生的独立危险因素。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂与胰高血糖素(GLP)-1受体激动剂都已明确对T2DM患者心血管有益处,但是又有不同的优缺点,本文就这两种药物对T2DM患者心血管的影响作一综述。Patients with type 2 diabetes mellitus(T2DM)are prone to complicate microvascular and macrovascular diseases,which is an independent risk factor of cardiovascular diseases.It has been confirmed that sodium-glucose cotransporter 2(SGLT2)inhibitors and glucagon like peptide(GLP)-1 receptor agonists can benefit cardiovascular system in T2DM patients,while they possess different advantages and disadvantages.The present article makes a review on influence of these two drugs on cardiovascular system in T2DM patients.

关 键 词：心血管疾病 糖尿病 2型 钠-葡萄糖转运蛋白质类 

分 类 号：R54[医药卫生—心血管疾病]